Anti-NMDA receptor encephalitis secondary prevention: Difference between revisions

	Anti-NMDA receptor encephalitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Anti-NMDA receptor encephalitis from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Anti-NMDA receptor encephalitis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Anti-NMDA receptor encephalitis secondary prevention
CDC on Anti-NMDA receptor encephalitis secondary prevention
Anti-NMDA receptor encephalitis secondary prevention in the news
Blogs on Anti-NMDA receptor encephalitis secondary prevention
Directions to Hospitals Treating Anti-NMDA receptor encephalitis
Risk calculators and risk factors for Anti-NMDA receptor encephalitis secondary prevention

Revision as of 17:31, 13 May 2023

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] AE Dheeraj Makkar, M.D.[2]

Secondary prevention measures include:

1. Education and Awareness: Increasing awareness among healthcare professionals, including neurologists, psychiatrists, and primary care providers, about the clinical presentation and diagnostic criteria of anti-NMDA encephalitis can facilitate early identification and intervention.

2. Diagnostic Workup: Implementing a standardized diagnostic workup, including brain imaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and antibody testing, can aid in confirming the diagnosis and guiding appropriate treatment.

3. Timely Initiation of Treatment: Early initiation of immunotherapy, such as corticosteroids, immune plasmapheresis, intravenous immunoglobulins, and rituximab, has been associated with better outcomes and reduced morbidity and mortality. Prompt removal of the underlying tumor, if present, is also important.

4. Multidisciplinary Approach: Collaboration among neurologists, psychiatrists, immunologists, and other specialists is essential for a comprehensive evaluation, management, and follow-up care of patients with anti-NMDA encephalitis.

@@ Line 6: / Line 6: @@
 ==Secondary Prevention==
-Secondary prevention of anti-NMDA encephalitis involves strategies aimed at early detection, timely intervention, and management to prevent disease progression and complications. Since anti-NMDA encephalitis often presents with neuropsychiatric symptoms, prompt recognition and appropriate referral to specialized medical care are crucial. Secondary prevention measures include:
+Secondary prevention measures include:
 *1. Education and Awareness: Increasing awareness among healthcare professionals, including neurologists, psychiatrists, and primary care providers, about the clinical presentation and diagnostic criteria of anti-NMDA encephalitis can facilitate early identification and intervention.